International Society for Cellular Therapy and Bloom Burton & Co. Healthcare Investor Conference
AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics, Inc., a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack multiple types of cancers, today announced that it will present an abstract at the International Society for Cellular Therapy Annual Meeting (ISCT) in Montreal, and a company overview at the Bloom Burton & Co. Healthcare Investor Conference in Toronto, both on Thursday, May 3.
At the ISCT, Dr. Chris Helsen, Director of Platform Development, will be presenting during the “Cancer Immunotherapy” breakout plenary on May 3, 11:00am – 12:15pm ET. The abstract is titled T cells engineered with T-Cell Antigen Coupler (TAC) receptors display robust efficacy against solid and liquid tumor xenografts in the absence of any toxicity.
